NEW YORK, Feb. 18 (GenomeWeb News) - Nanogen on Wednesday reported a net loss of $5.9 million, or $0.25 per share, for its fourth quarter ending Dec. 31, 2003, compared to total revenues of $6.7 million, or $0.09 a share, in the year-ago quarter.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: genetic target for urothelial bladder cancer treatment, and more.
At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.
Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.
Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.